Equities

ReproCell Inc

ReproCell Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)130.00
  • Today's Change1.00 / 0.78%
  • Shares traded393.30k
  • 1 Year change-46.50%
  • Beta0.8124
Data delayed at least 20 minutes, as of Sep 20 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Share price forecast

The one analyst offering a 12 month price target expects ReproCell Inc share price to rise to 270.00 in the next year from the last price of 130.00.
High107.7%270.00
Med107.7%270.00
Low107.7%270.00

Earnings history & estimates in JPY

On Aug 13, 2024, ReproCell Inc reported 1st quarter 2025 losses of -0.841 per share.
Average growth rate-181.62%
ReproCell Inc reported annual 2024 losses of -0.37 per share on May 13, 2024.
Average growth rate+48.90%
More ▼

Revenue history & estimates in JPY

ReproCELL Incorporated had 1st quarter 2025 revenues of 620.00k. This was 11.51% above the prior year's 1st quarter results.
Average growth rate+2.86%
ReproCELL Incorporated had revenues for the full year 2024 of 2.43m. This was 17.85% below the prior year's results.
Average growth rate+23.83%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.